AI Stock Memo: LNTH - Lantheus - RankAlpha

LNTH

Rating neutralAI MemoPost-earnings T+3

Lantheus

As of 2026-05-09/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-09 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

LNTH-2501 FDA decision by June 29 remains a real but not clean upside hook • 2026-06-29

Expected move: -20%

Biggest risk

The quality of the print was mixed: PYLARIFY revenue fell 6.5%, adjusted operating income fell 10.5%, adjusted EPS fell 4.6%, and management reaffirmed rather than raised 2026 guidance, which supports a monitoring stance instead of a stronger bullish reset [#8-K-2026-05-07].

Invalidation

Break below $76 or thesis failure.

What would change my mind?

Primary-source Q1 results showed resilient total revenue, strong free cash flow, higher cash balances, DEFINITY growth, and continued portfolio broadening through Neuraceq, PYLARIFY TruVu, and the pending LNTH-2501/PNT2003 milestones [#8-K-2026-05-07].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-09

Base target

$88

p=45%

Bull target

$102

p=25%

Bear target

$76

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-earnings digestion stays mixed after Q1 beat but no raise
PYLARIFY TruVu launch readiness is the larger 2H26 value unlock
Primary-source Q1 results showed resilient total revenue, strong free cash flow, higher cash balances, DEFINITY growth, and continued portfolio broadening through Neuraceq, PYLARIFY TruVu, and the pending LNTH-2501/PNT2003 milestones [#8-K-2026-05-07].

BearKey bullets

Adjusted operating income fell to $129.1M from $144.3M and adjusted EPS fell to $1.46 from $1.53, showing margin pressure despite headline GAAP EPS strength [#8-K-2026-05-07].
LNTH-2501’s PDUFA date was pushed to June 29, 2026 for manufacturing-related review, so another delay or a more complicated approval path would likely pressure sentiment [#8-K-2026-05-07].
Management explicitly tied PYLARIFY TruVu’s rollout to PMF readiness, coding, coverage, payment, and customer adoption, leaving multiple execution dependencies before the Q4 2026 launch matters financially [#8-K-2026-05-07].

WatchKey bullets

LNTH-2501 FDA decision by June 29 remains a real but not clean upside hook

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $88 (p=45%)

Bull/Bear spread: -7% / -31%

Vs latest close: Bull -7% · Base -20% · Bear -31%

Scenario probabilities

Bull Target: $102 (p=25%)Base Target: $88 (p=45%)Bear Target: $76 (p=30%)

Commentary

This is a T+3 post-earnings monitoring setup, not a clean thesis change. Primary-source support is strong because the May 7, 2026 earnings release and 8-K were confirmed, but delayed analyst revision evidence remains thin. The stock was about $93.06 on 2026-05-09 versus the $91.00 anchor on 2026-05-07, implying only a modest positive reaction despite the reported beat/reaffirm framing. No usable social-context coverage was provided, so confidence stays moderate rather than high.

As of 2026-05-09 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-earnings digestion stays mixed after Q1 beat but no raise
PYLARIFY TruVu launch readiness is the larger 2H26 value unlock

Scenarios

Bull Target (Scenario probability)

$102 / p=25% prob

Base Target (Scenario probability)

$88 / p=45% prob

Bear Target (Scenario probability)

$76 / p=30% prob

Price $110 as of 2026-07-02

Nearest Scenario: Bull (∆ 7%)

Targets vs latest close: Bull -7% · Base -20% · Bear -31%

Sentiment & Exposure

News Sentiment (30d)

0.05

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-06-29
LNTH-2501 FDA decision by June 29 remains a real but not clean upside hook
Management said the FDA extended the LNTH-2501 PDUFA date by three months to June 29, 2026 to review manufacturing-related information and said the extension was not tied to efficacy or safety; approval would add another NET imaging asset, but the delay keeps execution risk elevated [#8-K-2026-05-07].
Prob 60.00% • Move 10.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

Post-earnings digestion stays mixed after Q1 beat but no raise
2026-05-30
Q1 revenue rose 1.2% to $377.3M, GAAP EPS rose to $1.80, but adjusted EPS fell 4.6% to $1.46, PYLARIFY sales declined 6.5%, and full-year 2026 guidance was only reaffirmed rather than raised; the next few weeks are likely about whether investors reward cash generation and diversification or focus on slower core oncology growth [#8-K-2026-05-07].
Prob 70% • Move 6% • Priced-in 65%

Long-term Catalysts

Months to a year

PYLARIFY TruVu launch readiness is the larger 2H26 value unlock
2026-10-01
Lantheus said FDA approved PYLARIFY TruVu and that a phased geographic launch is planned to begin in Q4 2026, but the conversion still depends on manufacturing-site readiness plus coding, coverage, payment, and customer adoption; that makes it a meaningful but still execution-heavy growth bridge into 2027 [#8-K-2026-05-07].
Prob 65% • Move 14% • Priced-in 55%

Risks

Adjusted operating income fell to $129.1M from $144.3M and adjusted EPS fell to $1.46 from $1.53, showing margin pressure despite headline GAAP EPS strength [#8-K-2026-05-07].
LNTH-2501’s PDUFA date was pushed to June 29, 2026 for manufacturing-related review, so another delay or a more complicated approval path would likely pressure sentiment [#8-K-2026-05-07].
Management explicitly tied PYLARIFY TruVu’s rollout to PMF readiness, coding, coverage, payment, and customer adoption, leaving multiple execution dependencies before the Q4 2026 launch matters financially [#8-K-2026-05-07].
PNT2003 only has tentative approval and launch timing still depends on final FDA approval, patent litigation, and manufacturing/commercial planning [#8-K-2026-05-07].
PYLARIFY remained the largest business but Q1 sales fell 6.5% year over year, raising concern that core PSMA imaging growth is maturing before the TruVu conversion fully contributes [#8-K-2026-05-07].

Peers

Symbol	Summary
ABT	Abbott is a much broader medtech platform than LNTH, but it is a useful scale comparator for how diversified product portfolios and steadier hospital exposure usually command lower single-product sensitivity.
BSX	Boston Scientific is another broad medtech comparator rather than a direct radiopharma peer; compared with BSX, LNTH carries more binary regulatory and launch-timing risk around specific imaging assets.
BLCO	Bausch + Lomb is closer on market cap than on business model; the comparison mainly reinforces that LNTH’s peer set here is loose and that valuation should be read cautiously.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-09